These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31043141)

  • 1. Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6
    Martineau P; Watier H; Pèlegrin A; Turtoi A
    MAbs; 2019 Jul; 11(5):812-825. PubMed ID: 31043141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.
    Antunes A; Alvarez-Vallina L; Bertoglio F; Bouquin N; Cornen S; Duffieux F; Ferré P; Gillet R; Jorgensen C; Leick MB; Maillère B; Negre H; Pelegrin M; Poirier N; Reusch D; Robert B; Serre G; Vicari A; Villalba M; Volpers C; Vuddamalay G; Watier H; Wurch T; Zabeau L; Zielonka S; Zhang B; Beck A; Martineau P
    MAbs; 2023; 15(1):2211692. PubMed ID: 37184206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates: Design and development for therapy and imaging in and beyond cancer, LabEx MAbImprove industrial workshop, July 27-28, 2017, Tours, France.
    Martin C; Kizlik-Masson C; Pèlegrin A; Watier H; Viaud-Massuard MC; Joubert N
    MAbs; 2018; 10(2):210-221. PubMed ID: 29239690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody biosimilars: fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France.
    Guillon-Munos A; Daguet A; Watier H
    MAbs; 2014; 6(4):805-9. PubMed ID: 24714167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
    Hafner J
    J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAbDelivery: Administration routes for antibody therapy Third LabEx MAbImprove industrial workshop, July 2, 2015 Tours, France.
    Bodier-Montagutelli E; Respaud R; Watier H; Guillon-Munos A
    MAbs; 2017; 9(4):579-585. PubMed ID: 28346048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human monoclonal antibodies for discovery, therapy, and vaccine acceleration.
    Andreano E; Seubert A; Rappuoli R
    Curr Opin Immunol; 2019 Aug; 59():130-134. PubMed ID: 31450054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MI-mAbs, pre-industrial demonstrator supported by PIA for the early validation of therapeutic targets using monoclonal antibodies].
    Romagné F
    Med Sci (Paris); 2019 Dec; 35(12):1202-1203. PubMed ID: 31903940
    [No Abstract]   [Full Text] [Related]  

  • 9. Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.
    Nessa MU; Rahman MA; Kabir Y
    Biomed Res Int; 2020; 2020():3038564. PubMed ID: 32908881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Immunotherapy: The Dawn of Antibody Cocktails.
    Marrocco I; Romaniello D; Yarden Y
    Methods Mol Biol; 2019; 1904():11-51. PubMed ID: 30539465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research and development of therapeutic mAbs: An analysis based on pipeline projects.
    Geng X; Kong X; Hu H; Chen J; Yang F; Liang H; Chen X; Hu Y
    Hum Vaccin Immunother; 2015; 11(12):2769-76. PubMed ID: 26211701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France.
    Pauwels PJ; Dumontet C; Reichert JM; Beck A; Goetsch L; Corvaia N; Klein C; Coiffier B; Teicher B
    MAbs; 2012; 4(4):434-44. PubMed ID: 22684281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda.
    Luo J; Nishikawa G; Prasad V
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2303-2311. PubMed ID: 31396700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates: current status and future directions.
    Perez HL; Cardarelli PM; Deshpande S; Gangwar S; Schroeder GM; Vite GD; Borzilleri RM
    Drug Discov Today; 2014 Jul; 19(7):869-81. PubMed ID: 24239727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art in anti-cancer mAbs.
    Chiavenna SM; Jaworski JP; Vendrell A
    J Biomed Sci; 2017 Feb; 24(1):15. PubMed ID: 28219375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody therapy of B cell lymphoma.
    Weiner GJ; Link BK
    Expert Opin Biol Ther; 2004 Mar; 4(3):375-85. PubMed ID: 15006731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges and opportunities for monoclonal antibody therapy in veterinary oncology.
    Beirão BC; Raposo T; Jain S; Hupp T; Argyle DJ
    Vet J; 2016 Dec; 218():40-50. PubMed ID: 27938708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions.
    Rodgers KR; Chou RC
    Biotechnol Adv; 2016 Nov; 34(6):1149-1158. PubMed ID: 27460206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.